Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Eng

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Breast Cancer Research and Treatment|October 9, 2003
A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancerJo Anne Zujewski, Jennifer Eng-Wong, Joyce O'Shaughnessy, et al.
Familial Cancer|June 20, 2012
Outcomes of a systems-level intervention offering breast cancer risk assessments to low-income underserved womenDarren Mays, McKane E Sharff, Tiffani A DeMarco, et al.
The Lancet. Oncology|December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA studyStephen J Luen, Roberto Salgado, Stephen Fox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Brigitte C Widemann, et al.
BMC Medical Research Methodology|April 29, 2009
Recruitment to a physical activity intervention study in women at increased risk of breast cancerLarissa A Korde, Amy Micheli, Ashley W Smith, et al.
The Lancet. Oncology|September 16, 2018
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 studyJosep Tabernero, Paulo M Hoff, Lin Shen, et al.
Cancer Research Communications|November 29, 2023
Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast CancerVikram Malhi, Priya Agarwal, Mary R Gates, et al.
Journal of Clinical Pharmacology|December 21, 2018
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding StudyWhitney P Kirschbrown, Chris Wynne, Matts Kågedal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Sandra M Swain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2017
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based TherapyAnder Urruticoechea, Mohammed Rizwanullah, Seock-Ah Im, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Breast Cancer Research and Treatment|October 9, 2003
A pilot study of dose intense doxorubicin and cyclophosphamide followed by infusional paclitaxel in high-risk primary breast cancerJo Anne Zujewski, Jennifer Eng-Wong, Joyce O'Shaughnessy, et al.
Familial Cancer|June 20, 2012
Outcomes of a systems-level intervention offering breast cancer risk assessments to low-income underserved womenDarren Mays, McKane E Sharff, Tiffani A DeMarco, et al.
The Lancet. Oncology|December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA studyStephen J Luen, Roberto Salgado, Stephen Fox, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2005
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Brigitte C Widemann, et al.
BMC Medical Research Methodology|April 29, 2009
Recruitment to a physical activity intervention study in women at increased risk of breast cancerLarissa A Korde, Amy Micheli, Ashley W Smith, et al.
The Lancet. Oncology|September 16, 2018
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 studyJosep Tabernero, Paulo M Hoff, Lin Shen, et al.
Cancer Research Communications|November 29, 2023
Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast CancerVikram Malhi, Priya Agarwal, Mary R Gates, et al.
Journal of Clinical Pharmacology|December 21, 2018
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding StudyWhitney P Kirschbrown, Chris Wynne, Matts Kågedal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancerPeter F Lebowitz, Jennifer Eng-Wong, Sandra M Swain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2017
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based TherapyAnder Urruticoechea, Mohammed Rizwanullah, Seock-Ah Im, et al.
Pageof 7